LIVIA Group Acquires Patheon Facility in Capua, Italy

Livia Group, a German-based industrial holding, has entered into an agreement to acquire the Capua manufacturing facility and associated employees from Patheon, a leading global provider of outsourced contract development and manufacturing (CDMO) services for the pharma and biopharma industries. Capua, one of the world’s largest independent microbial fermentation-based manufacturing facilities with 1,400m³ fermentor capacity, represents an exceptional investment opportunity for Livia in the highly attractive market of enzymes and small molecules.

“Livia Group is enthusiastic about working with Capua to build on their existing strong market position, through a focus on product development, a revitalized sales function and improved production efficiency,” said Peter Löw, chief executive officer and founder, Livia Group.

Capua delivers enzymes, therapeutic proteins and high-value small molecules for applications in food, feed, pharma, agrochemical and fine chemical industry. The facility is both FDA and EMEA (Pharma cGMPs) approved as well as ISO 14001 certified and serves customers in more than 60 countries. In addition to its regular production, Capua offers pilot plant capabilities for customized product development, process scale-up and validation.

“We are very pleased to find a buyer for the Capua facility that is focused on servicing existing customers and adding new ones,” said Lukas Utiger, president drug substance services, Patheon. “Selling the Capua site is part of Patheon’s efforts to focus its core business strategy as a leading global provider of outsourced, end-to-end pharmaceutical development and manufacturing services. We elected to sell the operations to Livia Group, who is very focused on growing the operations and continuing to provide a positive work environment for employees.”